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Introduction
B-cell chronic lymphocytic leukaemia (B-CLL) is a
disease characterized by great clinical, phenotypic and
prognostic heterogeneity. Its heterogeneity reflects in
diverse genome gene expression profiles, including
ZAP-70 (zeta-chain-associated protein kinase 70) and
CD38 (cluster of differentiation 38) genes, different
IgV (immunoglobulin variable region) gene mutations
or their absence. B-CLL originates from B lympho-
cytes that may differ in the activation level, maturation
state or cellular subgroups in peripheral blood. The
essence of the disease is continuous complementing
replacement of dying B-CLL cells with daughter
leukaemic lymphocytes. About 0.1% – 1% of total
tumour cells arise every day [1]. It was proved that B-
CLL is an accumulative disease with higher levels of
proliferation than it was earlier thought [2]. The accu-
mulation of neoplastic cells impairs the equilibrium
between cell death [inhibited by accumulation of the
anti-apoptotic protein BCL2 (B-cell lymphoma protein
2)] and cell proliferation [3]. Tumour progression in B-
CLL seems to result in gradual accumulation of the
clone of resting B lymphocytes in the early phases
(G0/G1) of the cell cycle.
In B-CLL, like in other mammalian tumours, the
G1 cell cycle phase is deregulated. The crucial genetic
factors responsible for that deregulation remain unde-
termined. 
The cell cycle progression in normal mammalian
cells is governed by interactions between cyclins,
cyclin-dependent kinases (cdks) and cyclin-dependent
kinase inhibitors. Cyclin D2 seems to play a special
role in the regulation of B lymphocytes passing
through the G1 phase restriction point [4]. The
inhibitory effect on the cdks or cdk-cyclin complexes
is exerted by cdk inhibitors, e.g. p21WAF1/CIP1 (cyclin-
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dependent kinase inhibitor 1A) and p27Kip1 (cyclin-
dependent kinase inhibitor 1B) proteins [5].
p21WAF1/CIP1 inhibits the cell cycle in the G1/S
phase whereas p27Kip1 acts both as a cyclin-depend-
ent kinase activator and inhibitor [6,7]. The common-
est anomalies in B-CLL occur in the G1 phase and
G1/S restriction point. Most of the proto-oncogenes
and suppressor genes take control at that level, e.g. c-
Myc (v-myc myelocytomatosis viral oncogene
homolog) proto-oncogene and TP-53 (tumor protein
53 gene) suppressor gene. c-Myc is required for cell
proliferation.
Deregulation of c-Myc gene expression in many
human tumours is associated with poor prognosis and
indicates the key role of this oncogene in tumour pro-
gression [8]. However, p53 (tumor protein 53) is
important in multicellular organisms, where it regu-
lates the cell cycle and functions as a tumour suppres-
sor preventing cancer. Moreover, it can arrest the cell
cycle at the G 1/S restriction point upon recognition of
DNA damage. p53 is essential to prevent the transmis-
sion of genetic disorders to daughter cells. 
Unfortunately, TP-53 suppressor gene dysfunction is
observed in 50% of all tumours. The cyclin D2 gene is
one of the targets of both p53 and c-Myc proteins [9].
The wild-type p53 protein induces p21WAF1/CIP1 expres-
sion. The expression level of the p21 cell cycle inhibitor
is considered a marker of proper function of p53 as a
transcription activator. Increased levels of p21 expres-
sion reflect p53 overexpression caused by DNA damage
[10]. Most of the peripheral blood CLL lymphocytes are
arrested in the G0/G1 phase of the cell cycle, which is
mainly attributed to high p27 protein expression [11,12].
B-CLL, like other tumours, is characterized by
growth abnormalities. The aim of our study was to
determine c-Myc, TP-53, cyclin D2, p21WAF1/CIP1,
p27KIP1 mRNA expression in B-CLL lymphocytes and
its connection with disease progression.
Materials and methods
Patients. The study was conducted in peripheral blood lympho-
cytes of 40 patients diagnosed with chronic lymhocytic B-cell
leukaemia (B-CLL). The study cohort was recruited from the pre-
viously untreated, B-CLL patients of the Haematooncology and
Bone Marrow Transplantation Department, Medical University of
Lublin, Poland. The follow up period was four years. The control
group included 16 healthy volunteers, 5 females and 11 males of
comparables ages (median 62, range 38±79). The disease stages
were determined according to the Rai classification [13]. Clinical
data are presented in Table 1.
Flow cytometry analysis. The study was conducted in peripheral
blood lymphocytes obtained using the standard Böyum method
[14]. The immunophenotype was detected by flow cytometry with
monoclonal antibodies selectively binding the following antigens:
CD5 PE /CD19 FITC (Serotec/Serotec), CXCR4 PE/ CD19 FITC
(Becton Dickinson/ Becton Dickinson), CD23 PE/ CD19 PE-Cy5
(DacoCytomation/ Becton Dickinson), CD21 FITC/ CD19 PE-Cy
(DacoCytomation/ Becton Dickinson).
RNase Protection Assay (RPA). Total RNA was extracted from
peripheral blood lymphocytes using TRI Reagent and was subject-
ed to ribonuclease protection assay (RPA). Detection of studied
mRNA genes was performed with RPA system (RiboQuant,
Pharmingen, San Diego, CA). Multiprobe custom template sets
(p53, CXCR4, p27, p21, cycD2, c-myc) and two housekeeping
genes, L32 and glyceraldehydes-3-phosphate dehydrogenase
(GAPDH), were used for in vitro transcription using T7 RNA poly-
merase to direct synthesis of highly specific [32P]-labeled antisense
RNA mixtures. Each template set was transcribed using Riboprobe
system (Promega, Madison, WI) in the presence of [32P] uridine
triphosphate (UTP) (3000 Ci/mmol, NEN, Boston, MA). Total
RNA (20 μg) was hybridized with [32P]-labeled antisense RNAs at
56°C overnight and was subjected to ribonuclease treatment. Pro-
tected fragments were precipitated and separated on a 5% acry-
lamide gel. Electrophoresis was conducted in Consort EV233 under
the following conditions: 45W, 1500V, 2h. Signal detection was
performed by autoradiography with the use of X-ray film cassette
placed in -20°C. The X-ray was scanned and optical density of each
band was analysed using the Gel Scanv1.13 (Kucharczyk).
Ethical issues. The study was approved by the ethics committee of
Medical University in Lublin and written informed consent was
obtained from patients for the use of the clinical specimens for
research.
Statistical analysis. Experimental data was subjected to statistical
analysis using Statistica 6.0 software (Kaplan-Meier's survival
analysis, log-rank and Spearman rank correlation). The differences
were considered significant at p<0.05. 
Results
The gene expression was defined as a quotient of opti-
cal density of the gene band studied and optical densi-
ty of L32 (60S ribosomal protein L32 gene) house-
keeping gene band (Figs 1 and 2). 
Another issue analysed was a link between p53
expression and disease progression. For this purpose,
patients were divided into two groups with high and
low p53 expression levels. The highest value of nor-
mal p53 expression in peripheral blood lymphocytes
of healthy volunteers was considered a discriminating
value. According to the normal distribution theory, the
upper limit of the parameter range is the sum of mean
(X) and two standard deviations (2SD): X+ 2SD=
0.095+ 2 x 0.074=0.24.
The Kaplan-Meier's survival analysis was used for
two groups of B-CLL patients with the p53 expression
level higher and lower than 0.24 (higher and lower
than the upper limit of the normal p53 expression
range). The period between the diagnosis and onset of
treatment or latest follow up was analysed. 
Patients with the p53 mRNA expression levels
higher than 0.24 had shorter treatment-free survival
than the other group (p=0.03) (Fig. 3). As seen in Fig.
3, three years after the diagnosis, the number of
untreated patients with high p53 expression levels
declined to zero, i.e. each patient in this group received
cytotoxic treatment.    
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In two patients (No. 8 and 10), the c-Myc mRNA
expression level was surprisingly high (Fig. 4). To
analyse this phenomenon, the Kaplan-Meier method was
used. In unstimulated B-CLL cells, the c-Myc expression
level is significantly lower in comparison with normal
lymphocytes [15]. With regard to this, the median c-Myc
mRNA expression in B-CLL patients was chosen as the
discriminating value (Mc-Myc=0.0604).
Kaplan-Meier's analysis implies that patients with
higher c-Myc mRNA expression levels had much
shorter treatment-free survival than those with lower 
c-Myc expression levels. 
Moreover, Kaplan-Meier's analysis was carried out
in groups with different cyclin D2 mRNA expression.
The median cyclin D2 mRNA expression level in B-
CLL patients was considered the discriminating value
(M Cyclin D2=0.19). Cyclin D2 mRNA expression levels
defined by this value were not related to treatment-free
survival (p=0.14) (Fig. 5). 
In four randomly selected patients, gene expression
analysis was repeated one year after the diagnosis.
During this period, the patients did not receive any
cytotoxic treatment. The repeated analysis indicated a
gradual increase in expression of each gene studied.
The highest increase was noted in the patient with pro-
gressive disease (LDT<6 months, treatment-free sur-
vival – 21 months). 
To explain the above observation further, the corre-
lation analysis between the parameters studied and Rai
stages was conducted (Table 2, Fig. 6). 
The results suggest that the expression level of p53,
cyclin D2 and c-Myc was correlated with the Rai stage
of the disease; the p27 and Rai stage correlation was
near statistical significance (p=0.066). The p21 expres-
sion level did not correlate with the Rai stage. 
Fig. 1. Electrophoresis of hybrids of
the probe and gene transcripts stud-
ied. The identification of the consec-
utive bands was performed based on
the calibration curve traced accord-
ing to the manufacturer's instruc-
tions. Arrowheads mark the bands of
highly expressed c-Myc mRNA in
patients No. 8 and 10. Bands molec-
ular weight in nucleotides – nt (pro-
tected fragments) is marked on the
right side of the figure.
Fig. 2. An example of expression level analysis of the studied
genes in Gel Scan v1.13 computer programme. Numbered peaks
correspond to 3- p53, 5- p27, 6- p21, 7- cyclin D2, 8- c-Myc and
9-L32. The curve deflection depended on the magnitude and inten-
sity of the band and was correlated with the amount of the radioac-
tive isotope bound. The relative optical density was defined as a
quotient of the optical density of the gene band studied and opti-
cal density of L32 housekeeping gene.
Table 1. Patients clinical data.
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Discussion
Cell cycle progression is regulated by both intracellu-
lar and extracellular control mechanisms. Intracellular
control guarantees that cell cycle progression is
stopped in response to DNA damage, whereas extra-
cellular factors may determine the cell proliferation,
differentiation or apoptosis.  New evidence suggests
that antigenic stimulation, along with interactions with
accessory cells and cytokines, is a promoting factor in
CLL that stimulates the proliferation of CLL cells and
allows them to avoid apoptosis. In vivo studies using
nonradioactive methods suggest that CLL cells are
more dynamic than is usually appreciated [1]. This
dynamic process is also composed of cells that prolif-
erate and die, often at appreciable levels. 
In our study, we specifically investigated the gene
expression of five key cell cycle regulators: TP 53, c-
Myc, cyclin D2, p21 WAF1/CIP1 and p27KIP1, which pri-
marily regulate the G1 phase of the cell cycle, or S
Fig. 3. A high p53 expression level
as a negative prognostic factor indi-
cating shorter treatment-free sur-
vival. The period between diagnosis
and initiation of treatment was
analysed.   Patients with p53 expres-
sion levels, estimated as the relative
optical density of the proper band,
higher than the border value of 0.24,
required the institution of treatment
earlier compared to patients with
lower p53 expression levels. After
approximately 36 months, the num-
ber of untreated patients in the
p53>0.24 group declined to zero
(blue curve), i.e. each patient in this
group underwent treatment. 
Fig. 4. A high c-Myc expression
level as a negative prognostic factor
indicating shorter  treatment-free
survival. The period between diag-
nosis and initiation of treatment
was analysed. The number of
untreated patients decreased over
time. The discriminating value-
0.0604 was the median c-Myc
expression level in B-CLL patients.
Treatment-free survival in groups
with high and low c-Myc mRNA
expression levels varied in a statis-
tically significant way (p=0.0028). 
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phase entry and ultimately control the proliferation
and cell growth. We analyzed mRNA expression levels
of those genes and their role in B-CLL progression.
Statistical correlation analysis of TP53, cyclin D2, c-
Myc, p21 WAF1/CIP1 and  p27KIP1 expression in B-CLL
patients with different Rai stages demonstrated  that
progression of disease was accompanied by increases in
p53, cyclin D2 and  c-Myc mRNA expression. p27KIP1
expression was nearly statistically significant  whereas
p21 WAF1/CIP1 expression showed no such correlation.
Moreover, we found that high expression of TP53 and
c-Myc genes was closely associated with more aggres-
sive disease course requiring earlier therapy.
Patients with high p53 expression were character-
ized by significantly increased β2- microglobulin
levels, reflecting high disease activity and correlat-
ing with advanced Rai stages. Similar observations
were published by Cordone et al. [16] and Ghia et al.
[17].
Such findings suggest that the disease progression
may lead to the selection of the damaged genome
clone, which is visible in increased p53 mRNA expres-
sion observed in our study. According to Pettitt et al.
[10], increased p53 expression always results in
increased p21WAF1/CIP1 levels. This feedback relation
seems to be much more complex. Kienle et al. [18]
found that the level of p21 mRNA expression was
abnormally high in patients with 17p13.1 deletion (p53
locus). It may be two fold higher than the one observed
in CLL patients without that structural chromosomal
aberration. Generally, the level of p21 mRNA does not
correlate with p21 protein expression. Abnormal, high
mRNA p21 WAF1/CIP1 levels, frequently without
increased protein expression levels, are observed in B-
CLL with deletions of chromosome 17p13.1 locus. In
such cases, p21 WAF1/CIP1 levels may be twice higher
than those of normal B-CLL karyotypes. Koníková
and Kusenda [19] suggest that decreased p21 WAF1/CIP1
protein expression in CLL patients may result from
high MDM2 (the murine double minute 2) protein
"activity", which is responsible for the p21 transport to
proteasomes. On the other hand, abnormally high
enzymatic activity of a proteasome itself [20] is likely
to decrease significantly the p21 protein level. Cell
cycle abnormalities may be the consequence of that
phenomenon, since the cells of low or undetectable
p21 WAF1/CIP1 protein expression are able to enter the
cell cycle much more easily, or even reach and pass the
S phase despite the accompanying DNA damage [21]. 
Fig. 5. A cyclin D2 expression level
as a negative prognostic factor of
treatment-free survival. The period
between diagnosis and initiation of
treatment was analysed. The number
of untreated patients decreased over
time. The discriminating value 0.19
was the median cyclin D2 expres-
sion level in B-CLL patients. Treat-
ment-free survival in groups with
high and low cyclin D2 mRNA
expression levels showed no statisti-
cal variation (p=0.14). 
Table 2. Correlation between gene expression levels and Rai
stages according to the Spearman R rank correlation coefficient
and p value. 
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Fig. 6. Rai stage and p53 (A – R=0.41; p=0.011),
cyclinD2 (B – R=0.35; p=0.033) and c-Myc (C –
R=0.41; p=0.011) correlation graphs.
A
B
C
An overwhelming majority of B-CLL lymphocytes
remains in the G0/G1 phase of cell cycle and this aner-
gic state largely depends on the p27 protein expression.
The p27Kip1 protein expression is found to be even
twofold higher in 80% of CLL compared to normal B
lymphocytes [15]. In our study a nearly statistically
significant correlation between p27 protein expression
and lymphocyte-doubling time was observed in CLL
patients. Our results are consistent with the ones pub-
lished by Vrhovac et al. [22]. They found that high
p27Kip1 protein expression in B-CLL correlated with
disease progression, faster lymphocyte-doubling time
and poor prognosis. More stable disease progression is
not accompanied by increased p27 protein expression
[22,23].
The family of cyclins is one of the most important
factors involved in the regulation of the cell cycle of
both normal and malignant cells. As far as cyclin D2 is
concerned, the gene for cyclin D2 (CCND2) is activat-
ed in the early G1 phase and may play a role in car-
cinogenesis, as its amplification has been found in sev-
eral malignancies including B-CLL [24]. Cyclin D2
expression depends on the degree of lymphocyte B
activation, which seems to increase in proliferating B-
CLL cells [25]. Cyclin D2 expression was demonstrat-
ed [26] to increase threefold upon induction of prolif-
eration of lymphocytes through the BCR (B cell recep-
tor) in "unmutated B-CLL." It proves a significant role
of cyclin D2 in B-CLL lymphocyte proliferation. We
demonstrated that cyclin D2 increased with disease
progression, which supports the hypothesis of consid-
erable amounts of B-CLL lymphocytes exit the quies-
cence state and enter the cell cycle.
Furthermore, some inducing factor(s) are
involved, which stimulate cyclin D2 expression in B-
CLL cells. The hypothesis is confirmed by the fact
that D-type cyclins are synthesized as long as growth
factors are present, and therefore, cyclin D has been
suggested to act as a growth factor sensor [27]. The
presence of cells with higher cyclin D2 expression
levels in peripheral blood may reflect their increased
proliferative index. Similarly, with the disease pro-
gression, cells with ZAP-70 and CD38 expression
may be observed, which are normally absent [28].
Our results are different from those reported by Paul
et al. [29], who did not find any correlation between
cyclin D2 mRNA expression and disease progression
according to the Rai stage. 
However, our study was carried out on lympho-
cytes of untreated B-CLL patients; Paul et al.
analysed lymphocytes of patients in the 3rd and 4th
Rai stage after chemotherapy, 4 weeks before the ini-
tiation of treatment. It is well known that at least one
of the chemotherapeutics administered in B-CLL
therapy, fludarabine, strongly impedes the cyclin D2
expression [30].
Moreover, we demonstrated a correlation
between increased mRNA c-Myc expression and B-
CLL progression, which is an unfavourable prognos-
tic factor. B-CLL patients with increased c-Myc
mRNA expression required shorter time to treatment
(TTT), which may indicate the selection of cells,
which transmit the proliferation- and not apoptosis-
stimulating signal. High c-Myc expression reflects
aberrant function of the DNA repair pathway, depen-
dant on p53 and/or ATM (ataxia telangiectasia
mutated) [31,32], which may be one of the charac-
teristic factors of B-CLL.  
It seems that mobilization of cell-cycle factors and
their overexpression in B-CLL is triggered by abnor-
mal BCR-mediated signals due to either as-yet-undis-
covered lesions of the signal transducing pathway or
still-elusive cytogenetic lesions responsible for the
neoplastic transformation. The reason why the signal
from BCR causes either cell cycle initiation or cell
death remains to be determined. Cross-linking of sur-
face IgM (Immunoglobulin M) in CLL cells may trig-
ger signal transduction that can cause or protect from
apoptosis [33,34], whereas cross-linking of surface
IgD invariably prevents apoptosis [33]. The two sur-
face isotypes express the same clone-specific antigen-
binding site and provide concordant signals in mature
B cells. The possibility that the B-CLL cell precursors
could be stimulated through receptors other than the
BCR should be taken under consideration. Bacterial
products such as LPS (lipopolysaccharide), CpG, or
peptidoglycans that bind to different Toll-like recep-
tors can directly stimulate B-cells [35,36].
Increased expression of the genes observed with
the disease progression may imply permanent exis-
tence of unknown growth factors in CLL, which are
capable of binding with cell receptors and transmitting
stimulatory signals to the cell nucleus leading to cell
cycle progression. Identification of stimulating anti-
gens, their receptors, signal transduction pathways and
still-elusive cytogenetic lesions responsible for neo-
plastic transformation in B-CLL is necessary to
explain the pathogenesis of the disease.
Periodic yet regular gene expression profiling may
be useful for monitoring the disease progression and
instituting proper, appropriately timed therapy. 
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